Albireo announces expanded phase 3 data on bylvay™ (odevixibat) and a3907 at upcoming easl international liver congress

– bylvay demonstrates rapid reductions in serum bile acids and long-term improvements in growth, sleep, and hepatic parameters –

ALBO Ratings Summary

ALBO Quant Ranking